Filing Details

Accession Number:
0001225208-11-020257
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-08-18 16:29:02
Reporting Period:
2011-08-17
Filing Date:
2011-08-18
Accepted Time:
2011-08-18 16:29:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
14272 Bristol Myers Squibb Co BMY Pharmaceutical Preparations (2834) 220790350
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1341069 C Joseph Caldarella 345 Park Avenue
New York NY 10154
Svp & Controller No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.10 Par Value Acquisiton 2011-08-17 13,781 $25.45 59,867 No 4 M Direct
Common Stock, $0.10 Par Value Disposition 2011-08-17 58 $28.46 59,809 No 4 S Direct
Common Stock, $0.10 Par Value Disposition 2011-08-17 760 $28.46 59,049 No 4 F Direct
Common Stock, $0.10 Par Value Disposition 2011-08-17 12,322 $28.46 46,727 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 F Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, $0.10 Par Value Option (right to buy) Disposition 2011-08-17 13,781 $25.45 13,781 $25.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-02-28 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.10 Par Value 1,492 Indirect By BMY Savings & Investment Program
Footnotes
  1. This transaction was executed in multiple trades from $28.4600 to $28.4700. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. Shares withheld for payment of taxes and fees upon exercise of stock options.
  3. Shares withheld for payment of exercise price upon exercise of stock options.
  4. Based on a plan statement as of the end of the most recent fiscal quarter.
  5. Twenty-five percent of the stock option award vested on each of the first, second, third and fourth anniversaries of the grant date, which was March 1, 2005.